Boston Scientific Corporation (NYSE:BSX) exchanged hands 6,655,800 shares versus average trading capacity of 8.57M shares, while its relative trading volume is 0.77. Boston Scientific Corporation (NYSE:BSX)’s total market worth is $34.03B along with 1.36B outstanding shares.
Insiders has most recently took part in a trading activity, Pierce David A, SVP and President, Endoscopy of the company in a transaction that occurred 3/3/2017 sold 25,012 shares of the stock. The stock was sold at a price of $25.01, for a total value of $625,668. Subsequent to the transaction Pierce David A owned a total of 25,600 shares of the stock.
In a separate transaction on 3/3/2017, Pratt Timothy A., EVP, CG & Chief Admin Officer sold 23,540 shares of the stock. The stock was sold at a price of $23,540, for a total worth of $588,846. Succeeding to the transaction Pratt Timothy A. owned overall 245,846 shares of the stock.
Moreover, Mackey Edward F, EVP, Operations sold 6,239 shares of the stock in a reserved transaction that ensued on 3/2/2017. At a price of $25.00, the stock was sold for an entire value of $155,975. Consequent to the transaction Mackey Edward F owned a total of 30,819 shares of the stock.
Currently, 0.20% shares of Boston Scientific Corporation (NYSE:BSX) are owned by insiders with -10.86% six-month change in the insider ownership. The insider filler data counts the number of monthly positions over 3 month and 12 month time spans. For Boston Scientific Corporation (NYSE:BSX) total 107 number of trades held during last 3 months and 154 during last 12 months, out of them 12 numbers of buys held in last 3 months and 22 buys in last 12 months. Whereas 95 numbers of sells held in last 3 months and 132 sells over the past 12 months.
For the duration of last three months Boston Scientific Corporation (NYSE:BSX)’s total number of shares bought are 661,300 and sold 782,239 from a total of 1,443,539 traded shares. During last twelve months 730,110 number of shares bought and 2,280,942 sold from a total of 3,011,052 shares traded. A net activity of 120,939 took place in the course of three months, while 1,550,832 during last twelve months. Insider trading information is derived from Forms 3 and 4 filings are filed with the U.S. Securities and Exchange Commission (SEC).
Boston Scientific Corporation (NYSE:BSX) ended last trading session at the price of $24.98 whereas a number of traders indicating mean target price will hit $28.07 over the next twelve months, mean value of price target most recently revised on 02/27/17. Boston Scientific Corporation (NYSE:BSX)’s highest estimates of price target are $30.00 and low forecast is $24.00 based on the opinion of 21 analysts. The price target estimates represents a standard deviation of 1.77. However brokerage recommendations suggests an ABR of 1.63 based on calls of 20 experts.
Boston Scientific Corporation (NYSE:BSX) is expected to release the earnings of its current quarter on 4/26/17. The company is expected to release $0.3 EPS during current quarter according to 23 analysts whereas the company reported $0.28 EPS during same quarter a year ago. For the current quarter the stock has a lowest EPS estimates of $0.29 and high estimate of $0.31. Boston Scientific Corporation (NYSE:BSX)’s average revenue estimates for the current quarter are $2.08B according to 20 number of analysts. However its lowest revenue estimates are $2.07B and highest revenue estimates are $2.1B. A year ago the company’s sales were $1.96B. Its yearly sales growth estimates are 6.00%. Past 5 years growth of Boston Scientific Corporation (NYSE:BSX) observed at 31.52%, and for the next five years the analysts that follow this company are expecting its growth at 12.45%.